COVID-19 technology appraisal recommendations: surveillance and rapid update process statement consultation
About the consultation
We’re developing a process for rapidly updating technology appraisal recommendations on medicines for COVID‑19. Triggers may include new clinical evidence or the emergence of a new variant of SARS‑CoV‑2 (the virus that causes COVID‑19). A draft process statement is being consulted on. It outlines how we intend to do surveillance and update recommendations. Your views are welcome, particularly on:
- Is the process as outlined a good basis for the committee to make decisions and update recommendations?
- Do you have any concerns about the process and, if so, any suggestions to address those concerns?
- Do you think there are any gaps in the process or areas that need further consideration?
- Register your organisation or comment as an individual
We are inviting comments from stakeholder organisations and individuals. These will be considered, but we will not be providing a formal response.
If you’re commenting for an organisation, your organisation needs to be registered as a stakeholder.
Consultation document
NICE General Consultation (PDF Version) Process Statement
Add your comments
You must use this Comments form.
You must declare any links with, or funding from, the tobacco industry.
Closing date for comments: 5 pm on 5 May 2023.